Science published a new way of fighting cancer to solve the mystery of lupus

In the past decade, the advent of cancer immunotherapy has revolutionized the treatment landscape of cancerScientists have identified several key "brake molecules", such as the popular immune checkpoint PD-1, which limits the immune system's efforts to wipe out evil cancer cellsTherefore, the therapy developed for these immunosuppressive factors can release the body's natural defenses and effectively attack tumorsProfessor Supin,Yale University, was a pioneer in making important contributions to cancer immunotherapyHe was the first to discover the existence of PD-L1 and to prove that PD-L1 is vital to the survival of tumorsNow, inhibitors of the molecular pathway of PD-1/PD-L1 have been successfully used in the treatment of several cancersin addition to the PD-1/PD-L1 pathway, Professor Showping has identified a number of new molecules and pathways in the field of tumor immunity, one of which is PD-1H (aka VISTA)They found that PD-1H, or PD-1 homologous, is an inhibitory molecule expressed on the surface of T lymphocytes and myelin cellsin a new paper published in the journal Science Translational Medicine, the team reported new features of PD-1H, re-expanding our understanding of immunosuppressive factors and helping us understand Lupus Eryhathemus, a disease that is in dire need of new treatmentsThis time, in contrast to cancer, they are "binding" the immune system to fight human diseasefamiliar with American drama may have heard the name Lupus through "DrHouse." Lupus is an autoimmune disease, that is, the immune system "reverses" attacks the body's own organ tissuetwo common types of lupus, one is disc-like lupus (DLE), the main impact on the skin, the face of the butterfly-shaped erythema is a classic manifestation of the patient;because the cause severity of the disease, the progression factors are not clear, the treatment of lupus is very limitedIn fact, in the past 60 years, only one drug in the world has been approved for SLE, and DLE has not been approvedFiguring out the key factors in the onset of lupus will undoubtedly be of great help in the development of new drugs in the study, scientists found that when mice lacked immunosuppressive factor PD-1H, more than one-third of young female mice developed symptoms of skin damage such as hair loss and erythema, and half developed problems with organs such as the heart, which are histologically similar to two types of lupus in humans , antinuclear antibodies that characterize lupus also increased with age in female mice lacking PD-1H "These findings also suggest that mice with missing PH-1H may be able to serve as a new animal model for studying the complex pathology of lupus erythematosus The study authors said in their paper female mice with PD-1H developed skin lesions similar to lupus (Photo: Source: Supplied) to further confirm the relationship between PD-1H and lupus, the researchers examined blood samples from dermatology and SLE patients in DLE patients Compared to the healthy control group, PD-1H was expressed in a wide range of immune cells in patients with lupus erythematosus " this molecule is clearly associated with the suppression of lupus erythematosus It also seems selective, as it does not have the same effect in several other autoimmune diseases Professor Showping said Skin samples from patients with lupus erythematosus show edgy activity is higher (Photo: Source: Supplied) Can PD-1H be used as a target for the treatment of lupus? To test this hypothesis, the scientists used a monoclonal antibody that activates PD-1H in mice with lupus models effect is obvious! After using PD-1H monociders, the mice not only delayed the onset of the disease, but also significantly improved skin problems In addition, the amplification of inflammatory cytokines, chematin factors, and immune cells decreased significantly, indicating a decrease in the immune system's aggression against its own tissues activation of PD-1H monoantigen (MH5A) delays the onset of lupus erythematosus mice and reduces symptoms (Photo: Source: 1) in addition to revealing the key role of PD-1H in the disease, the researchers also noted in the paper that, as an immune checkpoint, PD-1H's role has been more focused on tumor progression, and there are currently clinical trials that block PD-1H cancer Therefore, "in the future, when treating cancer by blocking PD-1H, understanding which autoimmune diseases are highly expressive with PD-1H may help predict possible organ-specific immune-related adverse events." The author of the paper said in the discussion section we congratulate Professor Seiping's team on publishing the new research and look forward to this finding providing a better understanding of immunosuppressive factors and autoimmune diseases, which will be a boon to patients at an early date Reference s Xue Han et al., (2019) PD-1H (VISTA) - mediated suppression of autoimmunity in and cutanus lupus erythematosus Science Translational Medicine DOI: 10.1126/scitranslmed.aax1159 Retrieved Dec 13, 2019, from https://news.yale.edu/2019/12/11/flipping-script-novel-cancer-therapy-leads-insights-lupus original title: "Professor OfPing's team of Science" sub-published, using new anti-cancer ideas to solve the mystery of lupus erythematosus